Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

O&G CasesGynaecological oncology — vagina

O&G Cases · Gynaecological oncology — vagina

Vaginal cancer MDT — staging and treatment-planning station

Staging and treatment-planning station on primary vaginal cancer. Tests the FIGO primary-vaginal definition, the verbatim staging applied to imaging, the radiotherapy-dominant management with brachytherapy, the narrow surgical role, and the HPV field effect. Includes assessor key and marking domains.

resus3 min readVerification in progress

Target exams

FRANZCOGMRCOGABOG
On this page
Study tools

Target exams

FRANZCOGMRCOGABOG
Prompt
A 58-year-old woman presents with three months of postcoital bleeding. A 3 cm ulcerated plaque on the upper posterior vaginal wall is biopsied and confirms squamous cell carcinoma. Her cervix is normal and her last cervical screen was normal six months ago. Pelvic MRI shows invasion into paravaginal tissues but not to the pelvic sidewall, with no hydronephrosis. CT shows no distant metastases. You are the gynaecology oncology registrar presenting her to the MDT.

Station brief

Format. Staging and treatment-planning station, approximately 12 minutes. You are the gynaecology oncology registrar presenting this woman to the multidisciplinary team meeting. The assessor plays the MDT chair and asks you to apply the FIGO definition, stage the tumour, and propose the treatment plan with its rationale. [1]

Candidate instruction. Confirm this is a primary vaginal cancer, assign the FIGO stage from the imaging, and propose the definitive management with drug specifics and the rationale for the chosen modality. Address the HPV field effect in your surveillance plan. [2]

Obstetrics & Gynaecology Pro

Continue reading

You have read the opening of this case. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]FIGO Committee on Gynecologic Oncology Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet, 2009.PMID 19322933
  2. [2]Nogueira-Rodrigues A, Oonk MHM, Lorusso D, Slomovitz B, Leitão MM Jr, Baiocchi G Comprehensive management of vulvovaginal cancers. CA Cancer J Clin, 2025.PMID 40377134
  3. [3]Jhingran A Updates in the treatment of vaginal cancer. Int J Gynecol Cancer, 2022.PMID 35256422
  4. [4]Kesic V, Carcopino X, Preti M, Vieira-Baptista P, Bevilacqua F, Bornstein J, et al. The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia. Int J Gynecol Cancer, 2023.PMID 36958755
  5. [5]Huang J, Cai M, Zhu Z Survival and prognostic factors in primary vaginal cancer: an analysis of 2004-2014 SEER data. Transl Cancer Res, 2020.PMID 35117314
Obstetrics & Gynaecology Pro

$29/ monthor $279 / year

The complete Obstetrics & Gynaecology library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousVaccine-hesitant woman at booking — communication and counselling stationAntenatal care — maternal immunisation